Kuwait Saudi Pharmaceutical Industries Company

Name

Kuwait Saudi Pharmaceutical Industries Company

Legal name

Kuwait Saudi Pharmaceutical Industries Company

Website

https://kspico.com

Company type

Private

Founded year

1980

Operating status

Operating

Short description

Kuwait Saudi Pharmaceutical Industries Company (KSPICO) is Kuwait's only pharmaceutical manufacturer, producing 120+ branded generic medicines across GMP-certified oral solid, oral liquid, semi-solid, and large-volume parenteral lines. A majority-owned subsidiary of listed Mezzan Holding KSCP, KSP supplies hospitals, pharmacies, and approximately 100 million patients across eight GCC and MENA markets via direct sales and a regional distributor network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceutical manufacturing
• Large volume parenterals production
• Oral solid dosage manufacturing
• Pharmaceutical contract manufacturing
• Hospital IV solutions supply

Headquarters

HQ city

Al Ajman

HQ country

United Arab Emirates

HQ region

Middle East

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: KSP manufactures and sells pharmaceutical products directly in Kuwait and through distributors across the Middle East. Products include prescription medications, OTC products, and hospital solutions covering cardiovascular, CNS, endocrine, gastrointestinal, infectious diseases, musculoskeletal, respiratory, and other therapeutic categories.
2. Toll Manufacturing: KSP entered into a localization agreement with Abbott to manufacture 26 high-quality medicines through toll manufacturing at their Kuwait facility. This partnership enables local production of Abbott products, positioning KSP as a contract manufacturer for global pharmaceutical companies.
3. Distribution Services: KSP distributes its own manufactured products as well as partnered products (such as Rosemont Pharmaceuticals oral liquid formulations) across GCC and MENA regions through a network of distributors, earning margins on product sales.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

KSPICO manufactures and distributes a portfolio of more than 120 pharmaceutical products across four production lines: oral solids (tablets and capsules), oral liquids (syrups and suspensions), semi-solids (creams, ointments, suppositories), and large volume parenterals (I.V. infusions and dialysis solutions). Products are sold directly in Kuwait and through a distributor network across the GCC and MENA, covering prescription therapeutics, OTC consumer brands, and hospital solutions under brands such as Panadrex, Fludrex, I-Profen, Diclofast, Loraday, Diclona, Aloxal, MINISEC, METAPHAGE, and CO-VAROTIN.

Product overview

KSPICO is a fully-integrated pharmaceutical company with development, manufacturing, and sales capabilities serving approximately 100 million patients regionally. The product portfolio exceeds 120 products across multiple manufacturing facilities organized into four divisions: Oral Solids (tablets, capsules, powders) with 1,200 million units annual capacity; Oral Liquids (syrups, suspensions) with 36 million bottles; Semi-Solids (suppositories, creams, ointments) with 24 million suppositories and 9 million tubes; and Large Volume Parenterals (LVP/SVP) with 18 million units. The product line includes prescription medications (cardiovascular, antidiabetic, antibiotics, CNS, GI), OTC consumer products (analgesics, antihistamines, cold/flu), hospital solutions (IV solutions, dialysis), and medical devices (Idrex nasal spray, eye drops).

Differentiator

Problem solved

Functional benefit

Brands

• Panadrex: Analgesic and antipyretic brand including tablets, syrup, drops, suppositories for children and infants
• I-Profen
• Fludrex
• Diclofast
• Loraday
• Diclona
• Aloxal
• IDREX

Products and services

• LVP (Large Volume Parenterals) Products IV infusion solutions including electrolyte solutions (sodium chloride, lactated ringer's, ringers), nutritional preparations (dextrose), osmotic diuretics (mannitol), plasma expanders (dextran), irrigation solutions, and hemodialysis/peritoneal dialysis concentrates, supplied to hospitals in Kuwait and across the GCC and MENA.
• SVP (Small Volume Parenterals) Products Small volume injectable antibiotics and analgesics including Roxicef (cefuroxime), Ciprofloxacin IV, Suprazole IV, and Paracetamol IV infusion, supplied to hospitals.
• Prescription Pharmaceuticals Portfolio Branded prescription medicines spanning cardiovascular (ACETAB captopril, CO-VAROTIN valsartan/HCTZ, FUSIX furosemide, TENOL atenolol, ROZTOR rosuvastatin), antidiabetic (METAPHAGE metformin), gastrointestinal (MINISEC omeprazole), and anti-infective (CLAVOMOX, Ropenem meropenem, CIFLOX ciprofloxacin, SUPRAZOLE metronidazole, ROXICEF cefuroxime) categories, dispensed via pharmacies and hospitals.
• OTC Consumer Brands (Panadrex, Fludrex, I-Profen, Diclofast, Loraday, Diclona, Aloxal) Over-the-counter consumer pharmaceutical brands for pain, fever, cold/flu, allergy, inflammation, and gastric relief, including Panadrex (paracetamol), Fludrex (cold/flu), I-Profen (ibuprofen), Diclofast and Diclona (diclofenac), Loraday (loratadine), and Aloxal (antacid suspension), sold through pharmacy networks in Kuwait and the Middle East.
• Medical Devices (Idrex Nasal Spray, Idrex Nasal Inhalation, Idrex Allergy Eye Drops, Polyflush Syringes) Medical device products including Idrex nasal spray and nasal inhalation with ectoin for bronchial asthma and allergic rhinitis, Idrex Allergy Eye Drops with ectoin 2% and hydroxyethyl cellulose, and Polyflush pre-filled normal saline syringes (3ml, 5ml, 10ml) for flushing indwelling vascular access devices.
• Toll Manufacturing Services for Abbott Contract manufacturing of 26 Abbott pharmaceutical products at KSPICO's GMP-certified Kuwait facility, established under a 2021 localization agreement between Mezzan Holding and Abbott Laboratories, positioning KSPICO as a local manufacturer of global pharmaceutical brands.
• Rosemont Pharmaceuticals Distribution Distribution of Rosemont Pharmaceuticals' oral liquid formulation range across GCC and MENA markets, addressing pediatric and geriatric patients with swallowing difficulties.

Quantifiable outcome

• Serving 100 million patients regionally
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Kuwait Pharmaceutical Association (KPA)coreStrategic or Co-development Partner · 1 April 2025Strategic partnership signed between KSP and Kuwait Pharmaceutical Association to elevate pharmacy profession expertise in Kuwait through scientific sponsorships, educational training programs, student internships, and collaborative events. Dr. Rashed Khazal represented KSP and Dr. Ahmad Taqi represented KPA.
• CognitusminorImplementation/ SI/ Consulting Partner · 1 November 2024Cognitus partnered with KSP to implement SAP S/4HANA Cloud, making KSP the first pharmaceutical company in Kuwait to implement this cutting-edge enterprise platform. The transition from legacy systems enables innovation and operational efficiency.
• Rosemont PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 December 2022KSP signed a Strategic Partnership Agreement with Rosemont Pharmaceuticals for distribution of their oral liquid formulation ranges in GCC and MENA regions. The agreement was signed at the British Embassy in Kuwait. These products support pediatric and geriatric patients with swallowing difficulties.
• Abbott LaboratoriescoreOEM/ Whitelabel/ Licensing Partner · 1 June 2021Mezzan Holding KSCP entered a localization agreement with Abbott via its subsidiary KSP to localize manufacturing of 26 high-quality medicines in Kuwait. KSP launched toll manufacturing of 26 Abbott products at its headquarters, marking the first pharmaceutical localization agreement of its kind in Kuwait. The partnership was signed in 2021 and manufacturing commenced in March 2022.
• ALSHIFA PHARMAminorStrategic or Co-development Partner · 1 January 2021KSP acquired ALSHIFA PHARMA as part of its expansion and portfolio development strategy.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Cipla: Indian-headquartered global generic pharmaceutical company with significant MENA presence. Comparable through its respiratory, antiretroviral, and generic therapeutic categories overlapping with KSP's portfolio, though at much larger scale.
• Hikma Pharmaceuticals: Jordan-headquartered multinational generic and specialty pharmaceutical company with extensive MENA operations. Comparable as a MENA-focused generics manufacturer with broader geographic reach, deeper pipeline, and listed status.
• Dr. Reddy's Laboratories: Indian-headquartered global pharmaceutical company with significant MENA operations. Comparable through generic product overlap (cardiovascular, GI, antibiotics) and active participation in GCC institutional tenders, though at larger scale and broader geographic reach.
• Aurobindo Pharma: Indian-headquartered global generic manufacturer with extensive MENA exports. Comparable through generic portfolio overlap (cardiovascular, antibiotics, CNS, GI) and ability to serve institutional tenders across GCC markets at competitive pricing.

Direct peers

• Gulf Pharmaceutical Industries (Julphar): UAE-based generic pharmaceutical manufacturer with diversified dosage forms (oral solids, injectables, biologics) and distribution across MENA. Directly comparable as a regional generic manufacturer with similar therapeutic breadth and GCC distribution focus.
• Tabuk Pharmaceuticals: Saudi-based pharmaceutical manufacturer producing generics, branded generics, and OTC products across MENA. Comparable in product mix (cardiovascular, antibiotics, CNS, GI), distribution model, and regional focus on GCC/MENA markets.
• EIPICO (Egyptian International Pharmaceutical Industries): Egypt's largest pharmaceutical manufacturer with comprehensive portfolio of generics across dosage forms. Comparable as a regional generic manufacturer serving MENA markets with similar product breadth and institutional customer base.
• Saudi Pharmaceutical Industries & Medical Appliances (SPIMACO): Saudi Arabia's leading generic pharmaceutical manufacturer with similar manufacturing capabilities across multiple dosage forms. Directly comparable as a GCC national champion pharma manufacturer serving similar institutional and retail channels.

Emerging players

• Eva Pharma: Egyptian pharmaceutical manufacturer with growing MENA presence across generics, biosimilars, and consumer health. Comparable in dosage form diversity and regional distribution model, though focused on broader African and MENA markets.

Regional players

• National Pharmaceuticals Industries Co. (NPIC): Kuwaiti pharmaceutical manufacturer with similar product categories. Comparable as a domestic peer in Kuwait; however, KSP holds unique position as the country's only full-scale manufacturer. Chaired by KSP board member Qusay Al-Awadhi.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/KSPICO-205842242775604
• LinkedInlinkedin.com/company/kuwait-saudi-pharmaceuticals-industries-company
• Instagraminstagram.com/kspico.kw

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kuwait Saudi Pharmaceutical Industries Company